DLA Piper advises Axsome Therapeutics in the closing of its US$225 million public offering

DLA Piper advised Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, in the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of US$75.00 per share. The aggregate gross proceeds to Axsome were US$225 million. The lead book running manager was Leerink Partners (formerly SVB Securities).

Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts and for other general corporate purposes.

“Congratulations to our longtime client Axsome in the success of its public offering,” said Emilio Ragosa, the DLA Piper partner who led the deal team. “On behalf of our team, it was a pleasure to advise Axsome and have an opportunity to demonstrate our extensive life sciences and pharmaceutical industry capabilities.”

In addition to Ragosa (Short Hills), the team that advised Axsome included FDA regulatory partners Bethany Hills (New York) and Christopher Mikson, M.D. (Philadelphia and Washington, DC) and corporate associates Nicholas Luciano (Short Hills) and Mandeep Kalra (New York).

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.